Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum CECT 7485
- Development stage
- Unknown
- Lead developer
- AB-BIOTICS
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum CECT 7485 is a specific probiotic bacterial strain, classified as a live biotherapeutic product, developed for human use. It has shown strain-specific capabilities in modulating intestinal permeability and the gut-brain axis, largely via increased acetylcholine production and antagonism of opportunistic gut pathogens. It is primarily studied as part of a probiotic formulation for the management of gastrointestinal conditions such as irritable bowel syndrome (IBS), and is also investigated for effects on mild cognitive impairment, sleep disorders comorbid with anxiety and depression, and other gut-brain axis-related disorders. Mechanistic findings indicate this strain can restore epithelial barrier function, enhance expression of cytoskeletal and tight junction proteins, and potentially support neurotransmitter balance through impacts on acetylcholine and GABA pathways. It is generally developed and manufactured by AB-Biotics, a Kaneka company[1][2][3][5].
- Other names
- Lactiplantibacillus plantarum CECT 7485
Beyond the preview
Go deeper on lactobacillus plantarum CECT 7485.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum CECT 7485.